StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Madrigal Pharmaceuticals's price to book ratio was 19.1× on Nov 11, 2026, against 21.7× a year earlier. Over the last 5 years it ranged from 4.1× to 465.3×, with a median of 14.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202619.1×−2.0
2025Dec 31, 202521.1×+12.5
2024Dec 31, 20248.7×−183.7
2023Dec 29, 2023192.3×−272.9
2022Dec 30, 2022465.3×+459.2
2021Dec 31, 20216.1×+0.1
2020Dec 31, 20205.9×+2.7
2019Dec 31, 20193.2×−0.4
2018Dec 31, 20183.6×−17.5
2017Dec 29, 201721.1×+16.5
2016Dec 30, 20164.6×+3.9
2015Dec 31, 20150.7×−2.2
2014Dec 31, 20142.8×−17.4
2013Dec 31, 201320.2×+6.1
2012Dec 31, 201214.1×+6.5
2011Dec 30, 20117.7×+0.8
2010Dec 31, 20106.8×–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?